In addition to effectively lowering glucose, incretin drugs, which include glucagon-like peptide 1 receptor (GLP1R) agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, can also reduce blood pressure, body weight, the risk of developing or worsening chronic kidney disease and/or atherosclerotic cardiovascular events, and the risk of death
G protein-coupled receptor kinases
Twice-daily topical GHK-Cu was associated with improvements in laxity, clarity, firmness, fine lines, wrinkles, pigmentation, and density
Independent third-party testing is performed on every lot
Tomar yerba mate Plant compounds found in yerba mate, such as mate saponins, polyphenols, caffeine, and theobromine, can positively affect GLP-1 levels
264 The outcomes of the currently ongoing FLOW study will further inform the therapeutic potential of GLP-1R analogues to improve renal and cardiovascular prognosis in patients with renal impairment and T2D